{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:24:32Z","timestamp":1791109472828,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.ejphar.2007.04.017","type":"journal-article","created":{"date-parts":[[2007,4,23]],"date-time":"2007-04-23T11:04:07Z","timestamp":1177326247000},"page":"50-58","source":"Crossref","is-referenced-by-count":22,"title":["Mitochondria, ciglitazone and liver: A neglected interaction in biochemical pharmacology"],"prefix":"10.1016","volume":"567","author":[{"given":"Roberto","family":"Scatena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Bottoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe E.","family":"Martorana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Vincenzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Botta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Giardina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2007.04.017_bib1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1073\/pnas.80.2.324","article-title":"Physiological and X-ray studies of potential antisickling agents","volume":"80","author":"Abraham","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2007.04.017_bib2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.tips.2005.03.003","article-title":"PPARs: therapeutic targets for metabolic disease","volume":"26","author":"Berger","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2007.04.017_bib3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1124\/jpet.104.068312","article-title":"Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I","volume":"311","author":"Brunmair","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2007.04.017_bib4","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.2337\/diabetes.53.4.1052","article-title":"Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions","volume":"53","author":"Brunmair","year":"2004","journal-title":"Diabetes."},{"key":"10.1016\/j.ejphar.2007.04.017_bib5","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1345\/aph.1D400","article-title":"Thiazolidinedione-induced congestive heart failure","volume":"38","author":"Cheng","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejphar.2007.04.017_bib6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/hep.20567","article-title":"Troglitazone and liver injury: in search of answers","volume":"41","author":"Chojkier","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2007.04.017_bib7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1042\/bj2570673","article-title":"Evidence that the production of acetate in rat hepatocytes is a predominantly cytoplasmic process","volume":"257","author":"Crabtree","year":"1989","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejphar.2007.04.017_bib8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7326\/0003-4819-131-4-199908170-00008","article-title":"Pharmacologic therapy for type 2 diabetes mellitus","volume":"131","author":"DeFronzo","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejphar.2007.04.017_bib9","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1210\/er.20.5.649","article-title":"Peroxisome proliferator-activated receptors: nuclear control of metabolism","volume":"20","author":"Desvergne","year":"1999","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ejphar.2007.04.017_bib10","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/S0140-6736(00)04960-6","article-title":"Lessons from the glitazones: a story of drug development","volume":"357","author":"Gale","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2007.04.017_bib11","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/0006-2952(93)90607-X","article-title":"Structural and metabolic requirements for activators of the peroxisome proliferator-activated receptor","volume":"46","author":"Gottlicher","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.04.017_bib12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1517\/14740338.2.6.581","article-title":"Hepatotoxicity of thiazolidinediones","volume":"2","author":"Isley","year":"2003","journal-title":"Expert Opin Drug Safety."},{"key":"10.1016\/j.ejphar.2007.04.017_bib13","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/347645a0","article-title":"Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators","volume":"347","author":"Issemann","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2007.04.017_bib14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/35013000","article-title":"Roles of PPARs in health disease","volume":"405","author":"Kersten","year":"2000","journal-title":"Nature."},{"key":"10.1016\/j.ejphar.2007.04.017_bib15","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMra021844","article-title":"Drug-induced hepatotoxicity","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2007.04.017_bib16","doi-asserted-by":"crossref","first-page":"10347","DOI":"10.1016\/S0021-9258(18)81625-8","article-title":"Free acetate production by rat hepatocytes during peroxisomal fatty acid and dicarboxylic acid oxidation","volume":"264","author":"Leighton","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2007.04.017_bib17","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1126\/science.1104343","article-title":"Mitochondrial dysfunction and type 2 diabetes","volume":"307","author":"Lowell","year":"2005","journal-title":"Science."},{"key":"10.1016\/j.ejphar.2007.04.017_bib18","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1097\/01.mcg.0000155548.91524.6e","article-title":"Drug-induced hepatotoxicity","volume":"39","author":"Maddrey","year":"2005","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.ejphar.2007.04.017_bib19","first-page":"8","article-title":"Serious liver injury. Leading reason for drug removals, restrictions","volume":"35","author":"Meadows","year":"2001","journal-title":"FDA Consum."},{"key":"10.1016\/j.ejphar.2007.04.017_bib20","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1248\/bpb.25.1509","article-title":"A metabolic switching hypothesis for the first step in the hypolipidemic effects of fibrates","volume":"25","author":"Motojima","year":"2002","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejphar.2007.04.017_bib21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.27.1.256","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association","volume":"27","author":"Nesto","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2007.04.017_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1042\/bj3100133","article-title":"Involvement of oxidants and oxidant-generating enzyme(s) in tumour-necrosis-factor-alpha-mediated apoptosis: role for lipoxygenase pathway but not mitochondrial respiratory chain","volume":"310","author":"O'Donnel","year":"1995","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejphar.2007.04.017_bib24","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(83)90870-X","article-title":"Bezafibrate lowers oxygen affinity of hemoglobin","volume":"2","author":"Perutz","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2007.04.017_bib23","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1021\/ja00265a036","article-title":"Hemoglobin as a receptor of drugs and peptides: X-ray studies of the stereochemistry of binding","volume":"108","author":"Perutz","year":"1986","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejphar.2007.04.017_bib25","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1126\/science.1082889","article-title":"Mitochondrial dysfunction in the elderly: possible role in insulin resistance","volume":"300","author":"Petersen","year":"2003","journal-title":"Science."},{"key":"10.1016\/j.ejphar.2007.04.017_bib26","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMoa031314","article-title":"Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes","volume":"350","author":"Petersen","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2007.04.017_bib27","series-title":"A Pratical Approach","first-page":"160","article-title":"An enzymatic approach to the study of the tricarboxylic acid cycle in mitochondria","author":"Robinson","year":"1987"},{"key":"10.1016\/j.ejphar.2007.04.017_bib28","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2125.1995.tb04405.x","article-title":"Effects of gemfibrozil on the oxygen transport properties of erythrocytes","volume":"39","author":"Scatena","year":"1995","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.04.017_bib29","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1021\/tx0341052","article-title":"Bezafibrate induces a mitochondrial derangement in human cell lines intriguing effects for a peroxisome proliferator","volume":"16","author":"Scatena","year":"2003","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejphar.2007.04.017_bib30","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.bbrc.2004.05.072","article-title":"Mitochondrial respiratory chain dysfunction, a non receptor-mediated effect of syntetic PPAR-ligands. Biochemical and pharmacological implications","volume":"319","author":"Scatena","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2007.04.017_bib31","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/15216540400008416","article-title":"Mitochondrial dysfunction by synthetic ligands of peroxisome proliferators activated receptors (PPARs)","volume":"56","author":"Scatena","year":"2004","journal-title":"IUBMB Life."},{"key":"10.1016\/j.ejphar.2007.04.017_bib32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0925-4439(93)90138-Q","article-title":"A carbon-13 nuclear magnetic resonance investigation of the metabolic fluxes associated with glucose metabolism in human erythrocytes","volume":"1182","author":"Schrader","year":"1993","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2007.04.017_bib33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1124\/pr.54.1.101","article-title":"Mitochondria as a pharmacological target","volume":"54","author":"Szewczyk","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2007.04.017_bib34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0140-6736(98)10364-1","article-title":"Medical significance of peroxisome proliferator-activated receptors","volume":"354","author":"Vamecq","year":"1999","journal-title":"Lancet."},{"key":"10.1016\/j.ejphar.2007.04.017_bib35","series-title":"The Pharmacological Basis of Therapeutics","first-page":"875","article-title":"Drugs used in the treatment of hyperlipoproteinemias, ninth ed","author":"Witzum","year":"1996"},{"key":"10.1016\/j.ejphar.2007.04.017_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10408449891344182","article-title":"Extraperoxisomal targets of peroxisome proliferators: mitochondrial, microsomal, and cytosolic effects. Implications for health and disease","volume":"28","author":"Youssef","year":"1998","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.ejphar.2007.04.017_bib37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/toxsci\/48.1.82","article-title":"The effect of peroxisome proliferators on mitochondrial bioenergetics","volume":"48","author":"Zhou","year":"1999","journal-title":"Toxicol. Sci."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299907004876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299907004876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T20:06:29Z","timestamp":1628798789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299907004876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":37,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S0014299907004876"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2007.04.017","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}